Gastrointestinal stromal tumours
Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …
Gastrointestinal stromal tumor: challenges and opportunities for a new decade
C Serrano, S George - Clinical Cancer Research, 2020 - AACR
Gastrointestinal stromal tumor (GIST) provides a paradigm to evaluate new molecularly
targeted therapies and to identify structural and functional mechanisms for drug response …
targeted therapies and to identify structural and functional mechanisms for drug response …
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
INTRIGUE was an open-label, phase 3 study in adult patients with advanced gastrointestinal
stromal tumor who had disease progression on or intolerance to imatinib and who were …
stromal tumor who had disease progression on or intolerance to imatinib and who were …
Current and emerging applications of droplet digital PCR in oncology: an updated review
S Olmedillas-López, R Olivera-Salazar… - Molecular Diagnosis & …, 2022 - Springer
In the era of personalized medicine and targeted therapies for the management of patients
with cancer, ultrasensitive detection methods for tumor genoty**, such as next-generation …
with cancer, ultrasensitive detection methods for tumor genoty**, such as next-generation …
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label …
JY Blay, Q Devin, F Duffaud, M Toulmonde… - The Lancet …, 2024 - thelancet.com
Background The long-term impact of tyrosine kinase inhibitor (TKI) discontinuation on
resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is …
resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is …
Leveraging the fragment length of circulating tumour DNA to improve molecular profiling of solid tumour malignancies with next-generation sequencing: a pathway to …
HR Underhill - Molecular diagnosis & therapy, 2021 - Springer
Circulating cell-free DNA (ccfDNA) has emerged as a promising diagnostic tool in oncology.
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …
Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward
MJ Lostes-Bardaji, D García-Illescas… - Therapeutic …, 2021 - journals.sagepub.com
Gastrointestinal stromal tumor (GIST) represents a paradigm for clinically effective targeted
inhibition of oncogenic driver mutations in cancer. Five drugs are currently positioned as the …
inhibition of oncogenic driver mutations in cancer. Five drugs are currently positioned as the …
[HTML][HTML] Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal …
Background The current treatment paradigm of imatinib-resistant metastatic gastrointestinal
stromal tumor (GIST) does not incorporate KIT/PDGFRA genotypes in therapeutic drug …
stromal tumor (GIST) does not incorporate KIT/PDGFRA genotypes in therapeutic drug …
[HTML][HTML] A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Background The administration of adjuvant imatinib during 3 years is indicated after
resection of primary localized GIST at high risk of recurrence, but many patients relapse …
resection of primary localized GIST at high risk of recurrence, but many patients relapse …
Association of combination of conformation-specific KIT inhibitors with clinical benefit in patients with refractory gastrointestinal stromal tumors: a phase 1b/2a …
AJ Wagner, PL Severson, AF Shields, A Patnaik… - JAMA …, 2021 - jamanetwork.com
Importance Many cancer subtypes, includingKIT-mutant gastrointestinal stromal tumors
(GISTs), are driven by activating mutations in tyrosine kinases and may initially respond to …
(GISTs), are driven by activating mutations in tyrosine kinases and may initially respond to …